Targeted Strategies for Today's Evolving Markets

MissionIR Blog

VolitionRx Ltd. (VNRX) is “One to Watch”

VolitionRx Ltd. is a life sciences company focused on bringing to market its inexpensive, accurate, and scalable cancer detection blood tests. The company intends to use its NuQR suite of products to fill a looming void in cancer diagnostic testing, for which there currently is only one blood test in common clinical use.

NuQR is based on VolitionRx’s proprietary NucleosomicsR technology, capable of measuring and identifying nucleosome structures in the blood. The company has secured strong intellectual property protection for its products, further strengthened by patent applications in the United States, Europe and worldwide. Following ongoing clinical trials and regulatory approval, VolitionRx will market its diagnostic and screening tests for individual cancers under the NuQR brand.

The company is currently conducting clinical trials for its first product, a diagnostic test for colorectal cancer. Colorectal cancer is the third most common cancer in the United States – current tests are expensive, invasive and unpleasant, resulting in a significant need for an improved alternative for colorectal diagnoses.

VolitionRx’s primary office and laboratory are based in Namur, Belgium, from which the company’s strong team of professionals spearhead corporate initiatives. The company’s executive management team is further supported by a scientific advisory board staffed with senior scientists from around the world, as well as a highly experienced board of directors.

For more information, visit www.volitionrx.com

Let us hear your thoughts below:

This entry was posted in Ones to Watch, VolitionRx Ltd. VNRX. Bookmark the permalink.

Comments are closed.